| Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. | |
| | |
MedLine Citation:
|
PMID: 21041432 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Background Higher intake of monounsaturated fat may raise high-density lipoprotein (HDL) cholesterol without raising low-density lipoprotein (LDL) cholesterol. We tested whether increasing the monounsaturated fat content of a diet proven effective for lowering LDL cholesterol (dietary portfolio) also modified other risk factors for cardiovascular disease, specifically by increasing HDL cholesterol, lowering serum triglyceride and further reducing the ratio of total to HDL cholesterol. Methods Twenty-four patients with hyperlipidemia consumed a therapeutic diet very low in saturated fat for one month and were then randomly assigned to a dietary portfolio low or high in monounsaturated fatty acid for another month. We supplied participants' food for the two-month period. Calorie intake was based on Harris-Benedict estimates for energy requirements. Results For patients who consumed the dietary portfolio high in monounsaturated fat, HDL cholesterol rose, whereas for those consuming the dietary portfolio low in monounsaturated fat, HDL cholesterol did not change. The 12.5% treatment difference was significant (0.12 mmol/L, 95% confidence interval [CI] 0.05 to 0.21, p = 0.003). The ratio of total to HDL cholesterol was reduced by 6.5% with the diet high in monounsaturated fat relative to the diet low in monounsaturated fat (-0.28, 95% CI -0.59 to -0.04, p = 0.025). Patients consuming the diet high in monounsaturated fat also had significantly higher concentrations of apolipoprotein AI, and their C-reactive protein was significantly lower. No treatment differences were seen for triglycerides, other lipids or body weight, and mean weight loss was similar for the diets high in monounsaturated fat (-0.8 kg) and low in monounsaturated fat (-1.2 kg). Interpretation Monounsaturated fat increased the effectiveness of a cholesterol-lowering dietary portfolio, despite statin-like reductions in LDL cholesterol. The potential benefits for cardiovascular risk were achieved through increases in HDL cholesterol, further reductions in the ratio of total to HDL cholesterol and reductions in C-reactive protein. (ClinicalTrials.gov trial register no. NCT00430430.). |
| | |
Authors:
|
David J A Jenkins; Laura Chiavaroli; Julia M W Wong; Cyril Kendall; Gary F Lewis; Edward Vidgen; Philip W Connelly; Lawrence A Leiter; Robert G Josse; Benoît Lamarche |
Publication Detail:
|
Type: Journal Article Date: 2010-11-01 |
Journal Detail:
|
Title: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne Volume: 182 ISSN: 1488-2329 ISO Abbreviation: CMAJ Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9711805 Medline TA: CMAJ Country: Canada |
Other Details:
|
Languages: eng Pagination: 1961-7 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Percutaneous liver biopsy: a cause of hepatic portal venous gas.
Next Document: Necrotic pulmonary nodules in secondary syphilis.